Kazia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group maintained a Buy rating on the stock and has a $20.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors that highlight Kazia Therapeutics’ strategic advancements and potential in the oncology space. The company has recently in-licensed a novel PD-L1 protein degrader, NDL2, which is a first-in-class development with no current competitors in the market. This acquisition not only expands Kazia’s pipeline but also positions it to potentially dominate the breast cancer treatment space, given the prevalence of PD-1 inhibitors in this area.
Additionally, Kazia’s ongoing development of paxalisib, particularly its incorporation into an AI-driven platform study for pediatric gliomas, presents a promising opportunity. The study aims to improve treatment response rates by utilizing AI algorithms to tailor treatments based on patient characteristics. The positive data already generated in glioblastoma multiforme (GBM) further supports the potential of paxalisib, and the pediatric study could de-risk its overall development. Overall, these strategic moves and the potential for unlocking further shareholder value underpin Rahman’s positive outlook and Buy rating for Kazia Therapeutics.